FDA lets bluebird resume trials for sickle cell gene therapy after cancer scare, but big questions linger over field
Bluebird bio announced that the FDA has lifted its holds on clinical trials for their gene therapies for sickle disease and beta-thalassemia, ending a 4 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
